RxDoctor Payments Data

Sara Hopper

Adult Health · Birmingham, ALNPI 1972054807

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (40.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Boehringer Ingelheim at 33.2% of the total. Reporting peaked in 2024 at $6,113 and has fallen 53.9% since, to $2,818 in 2025. Among adult health clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,040in general payments, 2019–2025

Across 410 payments — averaging $51.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$7K
  • Johnson & Johnson$5K
  • AbbVie$1K
  • Regeneron Healthcare Solutions, Inc.$925
  • EPI Health, LLC$900
  • Incyte Corporation$739
  • plus $5K from 19 others

What the payments were for

  • Consulting fees$4,86023%
  • Speaking & faculty fees$5,96628%
  • Travel & lodging$8064%
  • Food & beverage$8,60141%
  • Education$8074%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,040 in reported general payments places this provider in the 95th percentile of 308 adult health providers in Alabama.

See all adult health providers in Alabama

Medicare billing

Part B allowed, 2024
$52,315
Medicare patients
245
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa16$343,548
Cosentyx Unoready PenSecukinumab29$281,252
Dupixent PenDupilumab47$195,706
Humira(Cf) PenAdalimumab21$153,803
Dupixent SyringeDupilumab35$145,921
Taltz AutoinjectorIxekizumab11$74,131
Tacrolimus144$25,174
Clobetasol Propionate237$12,960
Betamethasone Dipropionate79$3,495
Fluorouracil41$3,205
Ketoconazole146$2,897
ValacyclovirValacyclovir Hcl41$1,781
Metronidazole20$1,709
Doxycycline Hyclate58$1,552
Fluocinonide38$1,476

Paid to pharmacies, not to this prescriber.

Other adult health in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →